Prosensa Holding said today the closing of its previously announced initial public offering. The IPO offered 6,900,000 of its ordinary shares of common stock. The initial public offering was valued at US$13 per share piece. This included an underwriter option of additional purchase for 900,000 ordinary shares pursuant to the exercise of the overallotment option. The ordinary shares started trading last June 28, 2013 on the Nasdaq Global Market under the trading symbol RNA.

A portion from the net proceeds of the initial public offering was intended to fund its current DMD development portfolio. In addition, it would also be used to fund its early stage DMD discovery work and DMD support projects. Other non-DMD projects would also be funded from the net proceeds of the sale. Another portion of the net proceeds would be used for working capital and general corporate purposes.

JP Morgan and Citigroup were the joint book running managers for the offering. Leerink Swann acted as the lead manager. Wedbush PacGrow Life Sciences, KBC Securities and Trout Capital were the co-managers for the offering.